Abstract

The rapid emergence of molecular diagnostic platforms has revolutionized the diagnostic approaches in hematology laboratory. Fluorescence in-situ hybridization, polymerase chain reaction and DNA sequencing are common techniques used in routine clinical laboratories for the diagnosis of hematological diseases. Different molecular techniques are indicated in different situations. This paper describes the utility of common molecular techniques. Fluorescence in-situ hybridization is specific for detection of chromosomal abnormalities using fluorescent labeled targeting probe. Polymerase chain reaction amplifies target DNA and reverse transcription polymerase chain reaction amplifies target RNA for the analysis of gene and its expression level. Real-time polymerase chain reaction is highly sensitive for detection of minimal residual disease in hemic malignancies. Gap-polymerase chain reaction is often employed for diagnosis of large deletions such as in alpha thalassemia. Allele-specific polymerase chain reaction is commonly used for single nucleotide polymorphism detection which is common in beta thalassemia, myeloproliferative neoplasm and acute leukemia. Inverse shifting-polymerase chain reaction can be employed for the detection of large genetic rearrangements such as those seen in hemophilia A. For genetically complex diseases such as hemophilia A, which involves a great variety of mutations in large genes, high resolution melting analysis can be used to scan for point mutations. Any suspected mutations are confirmed using post-PCR technologies, such as DNA sequencing. Although conventional diagnostic methods are able to provide a basic analysis in most cases, molecular technologies generate valuable genetic information that can refine diagnosis, better predict prognosis and facilitate disease monitoring.

Highlights

  • While labor-intensive manual tests and high-volume automations are routinely employed for clinical diagnostics, we are heading towards the era of personalized therapy using molecular platforms

  • Emerging molecular-cytogenetic techniques, such as fluorescence in situ hybridization (FISH), and other molecular technologies have overcome many of the drawbacks of conventional diagnostic methods

  • Pallisgaard et al have successfully established a multiplex RT-Polymerase Chain Reaction (PCR) protocol with 8 parallel PCR reactions for simultaneous detection of 29 chromosomal aberrations in leukemia, for example, BCR-ABL (e1a2, b2a2, b3a2) chimeric gene for acute lymphoid leukemia (ALL) and chronic myeloid leukemia (CML); MLL/AF6, MLL/AF6, MLL/AF6, MLL/AF6 in acute myeloid leukemia (AML); and NPM-RARA in acute promyelocytic leukemia (APL) [19]

Read more

Summary

Introduction

While labor-intensive manual tests and high-volume automations are routinely employed for clinical diagnostics, we are heading towards the era of personalized therapy using molecular platforms. FISH detects all molecular variants in CML and minimal residual disease (MRD) at low leukemic cell counts. FISH is often used in parallel with cytogenetics and/or other molecular techniques for diagnostics, confirmations and treatment monitoring. PCR is commonly used for detection of known mutations at the DNA level.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call